Epidemiology of cancer of the liver and intrahepatic bile ducts in an Australian population

Asian Pacific Journal of Cancer Prevention

Volumn 11, Issue 6, 2010, Pages 1479-1485

  Luke, Colin ^a   Price, Timothy ^a   Roder, David ^b  

^a QUEEN ELIZABETH HOSPITAL   (Australia)

^b CANCER COUNCIL SOUTH AUSTRALIA   (Australia)

Author keywords

Control; Incidence; Liver cancer; Mortality; Prevention; South Australia

Indexed keywords

EID: 79956085020     PISSN: 15137368     EISSN: 2476762X     Source Type: Journal    
DOI: None     Document Type: Article

References (60)

1. (ABS) Australian Bureau of Statistics (1998). 1996 census of population and housing. Socio-economic indexes for areas. Australian bureau of statistics, Canberra.
2. Adami HO, Chow WH, Nyrén CB, et al (1996). Excess risk of primary liver cancer in patients with diabetes mellitus. J Natl Cancer Inst, 88, 1472-7.
3. (AIHW) Australian Institute of Health and Welfare (2008). Diabetes. Australian facts 2008. Diabetes series no. 8. Cat. No. CVD 40. Australian Institute of Health and Welfare, Canberra.
4. (AIHW) Australian Institute of Health and Welfare (2010). Australian cancer incidence and mortality (ACIM) books. AIHW, Canberra.
5. (AIHW) Australian Institute of Health and Welfare, (CA) Cancer Australia and the (AACR) Australasian Association ofCancer Registries (2008). Cancer survival and prevalence in Australia. Cancers diagnosed from 1982 to 2004. Cancer Series no. 42. Cat. no. CAN 38. AIHW, Canberra.
6. Alam N, Robotin M, Baker D (2009). Epidemiology of primary liver cancer. Cancer Forum, 33, 88-92.
7. Altekruse SF, McGlynn KA, Reichman ME (2009). Hepatocellular carcinoma incidence, mortality, and survival trends in the United States from 1975 to 2005. J Clin Oncol, 27, 1485-91.
8. Armitage P, Berry G (1987). Statistical methods in medical research. Blackwell Scientific Publications, Oxford.
9. Australian Government, Preventative Health Taskforce (2008). Australia: the healthiest country by 2020. Discussion paper prepared by the national preventative health taskforce. Commonwealth of Australia, Canberra.
10. Bonett A, Roder D, Esterman A (1988). Cancer case-survival rates for South Australia: a comparison with US rates and a preliminary investigation of time trends. Med J Aust, 148, 556-9.
11. Bosch FX, Ribes J, Cléries R, et al (2005). Epidemiology of hepatocellular carcinoma. Clin Liver Dis, 9, 191-211.
12. Bosch FX, Ribes J, Diaz M, et al (2004). Primary liver cancer: worldwide incidence and trends. Gastroenterology, 127, S5-16.
13. (CCCR) Centre for Cancer Control Research (2001). Cancers of the digestive system. South Australian cancer statistics. monograph No. 1. Anti-Cancer Foundation, Adelaide.
14. (CCSA) Cancer Council South Australia (2003). Graphical presentation of cancer trends by country of birth, socioeconomic status, geographical location and diagnostic period. Cancer Council, Adelaide.
15. Condon JR, Armstrong BK, Barnes T, et al (2005). Cancer incidence and survival for Indigenous Australians in the Northern Territory. Aust NZ J Public Hlth, 29, 123-8.
16. Coory M, Thompson A, Ganguly I (2000). Cancer among people living in rural and remote Indigenous communities in Queensland. Med J Aust, 173, 301-4.
17. Corrao G, Ferrari P, Gatatola G (1995). Exploring the role of diet in modifying the effect of known disease determinants: application to risk factors of liver cirrhosis. Am J Epidemiol, 142, 1136-46.
18. Cottrell J, Street J, Chong A, et al (2007). Comparing cancer profiles and survival of Aboriginal and non-Aboriginal patients in South Australia: where are the opportunities for improving Aboriginal health? Asian Pac J Cancer Prev, 8, 495-501.
19. Cunningham J, Rumbold AR, Zhang X, et al (2008). Incidence, aetiology, and outcomes of cancer in Indigenous peoples in Australia. Lancet Oncol, 9, 585-95.
20. de Martel C, Plummer M, Franceschi S (2010). Cholangiocarcinoma: descriptive epidemiology and risk factors. Gastrenterol Clin Biol, 34, 173-80.
21. Dobson AJ, Kuulasmaa K, Eberle E, et al (1991). Confidence intervals for weighted sums of Poisson parameters. Stat Med, 10, 457-62.
22. Endo I, Gonen M, Yopp AC, et al (2008). Intrahepatic cholangiocarcinoma: rising frequency, improved survival, and determinants of outcome after resection. Ann Surg, 248, 84-96.
23. Faivre J, Forman D, Estéve J, et al (1998). Survival of patients with primary liver cancer, pancreatic cancer and biliary tract cancer in Europe. Eur J Cancer, 34, 2184-90.
24. Ferlay J, Shin HR, Bray F, et al (2010). GLOBOCAN 2008. Cancer incidence and mortality worldwide: IARC CancerBase No. 10 [Internet]. IARC, Lyon.
25. Fritz A, Percy C, Jack A, et al (2000). International classification of diseases for oncology. 3rd edit. WHO, Geneva.
26. Horner MJ, Ries LAG, Krapcho M, et al (2009). SEER Cancerstatistics review, 1975-2006. National Cancer Institute, Bethesda, MD.
27. Hsing AW, Gao YT, Devesa SS, et al (1998). Rising incidence of biliary tract cancers in Shanghai, China. Int J Cancer, 75, 368-70.
28. Ioannou GN, Splan MF, Weiss NS, et al (2007). Incidence and predictors of hepatocellular carcinoma in patients with cirrhosis. Clin Gastroenterol Hepatol, 5, 938-45.
29. Kaczynski J, Hansson G, Wallerstedt S (1998). Incidence, etiologic aspects and clinicopathologic features in intrahepatic cholangiocellular carcinoma - a study of 51 cases from a low endemicity area. Acta Oncol, 37, 77-83.
30. Kahn SA, Toledano MB, Taylor-Robinson SD (2008). Epidemiology, risk factors, and pathogenesis of cholangiocarcinomas. HPB (Oxford), 10, 77-82.
31. Kemik O, Sumer A, Kemik AS, et al (2010). Human vascular adhesion protein (VAP-1): serum levels for hepatocellular carcinoma in non-alcoholic fatty liver disease. World J Surg Oncol, 8, 83.
32. Kita Y, Mizukushi E, Takamura T, et al (2007). Impact of diabetes mellitus on prognosis of patients infected with hepatitis C virus. Metabolism, 56, 1682-8.
33. Klatsky A, Armstrong M (1992). Alcohol, smoking, coffee, and cirrhosis. Am J Epidemiol, 136, 1248-57.
34. Kobayashi M, Ikeda K, Saitoh S, et al (2000). Incidence of primary cholangiocellular carcinoma of the liver in Japanese patients with hepatitis C virus-related cirrhosis. Cancer, 88, 2471-7.
35. La Vecchia C, Lucchini F, Franceschi S, et al (2000). Trends in mortality from primary liver cancer in Europe. Eur J Cancer, 36, 909-15.
36. Law MG, Dore GJ, Bath N, et al (2003). Modeling hepatitis C virus incidence, prevalence and long-term sequelae in Australia, 2001. Int J Epidemiol, 32, 717-24.
37. Law MG, Roberts SK, Dore GJ, et al (2000). Primary hepatocellular carcinoma in Australia, 1978-1997: increasing incidence and mortality. Med J Aust, 173, 403-5.
38. Lindkvist B, Benito de Valle M, Gullberg B, et al (2010). Incidence and prevalence of primary sclerosing cholangitis in a defined adult population in Sweden. Hepatology, 52, 571-7.
39. NSW Health. NSW Cancer Registry Statistical Reporting Module (2010). Cancer Institute NSW, Sydney.
40. Nguyen VT, Law MG, Dore GJ (2009). Hepatitis B-related hepatocellular carcinoma: epidemiological characteristics and disease burden. J Viral Hepat, 16, 453-63.
41. Oh SW, Yoon YS, Shin SA (2005). Effects of excess weight on cancer incidence depending on cancer sites and histologic findings among men: Korea national health insurance corporation study. J Clin Oncol, 23, 4742-54.
42. O'Sullivan BG, Gidding HF, Law M, et al (2004). Estimates of chronic hepatitis B virus infection. Aust NZ J Public Hlth, 28, 212-6.
43. Patel T (2001). Increasing incidence and mortality of primary intrahepatic cholangiocarcinoma in the United States. Hepatology, 33, 353-7.
44. Patel T (2002). Worldwide trends in mortality from biliary tract malignancies. BMC Cancer, 2, 10.
45. Roder D (2005). Comparative cancer incidence, mortality and survival in Indigenous and non-Indigenous residents of South Australia and the Northern Territory. Cancer Forum, 29, 7-9.
46. (SACR) South Australian Cancer Registry (1997). Epidemiology of cancer in South Australia. Incidence, mortality and survival 1977 to 1996. Incidence and mortality 1996. Openbook Publishers, Adelaide.
47. (SACR) South Australian Cancer Registry (2000). Epidemiology of cancer in South Australia. Incidence, mortality andsurvival 1977 to 1999. Incidence and mortality 1999. Openbook Publishers, Adelaide.
48. Shin H, Lee C, Park H, et al (1996). Hepatitis B and C virus, Clonorchis sinensis for the risk of liver cancer: a case-control study in Pusan, Korea. Int J Epidemiol, 25, 933-40.
49. Srivantanakul P, Spriplung H, Deerasamee S (2004). Epidemiology of liver cancer: an overview. Asian Pac J Cancer Prev, 5, 118-25.
50. StataCorp (2005). Stata statistical software. Release 9.2. StataCorp LP, College Station, Texas.
51. Taylor-Robinson SD, Toledano MB, Arora S, et al (2001). Increase in mortality rates from intrahepatic cholangiocarcinoma in England and Wales 1968-1998. Gut, 48, 816-20.
52. Tischoff I, Tannapfel A (2007). Hepatocellular carcinoma and cholangiocarcinoma - different prognosis, pathogenesis and therapy. Zentralbl Chir, 132, 300-5.
53. Toso C, Mentha G, Kneteman NM, et al (2010). The place of downstaging for hepatocellular carcinoma. J Hepatol, 52, 930-6.
54. Valery PC, Coory M, Stirling J, et al (2006). Cancer diagnosis, treatment, and survival in Indigenous and non-Indigenous Australians: a matched cohort study. Lancet, 367, 1842-8.
55. Wan X, Mathews JD (1994). Primary hepatoocellular carcinoma in Aboriginal Australians. Aust J Public Hlth, 18, 286-90.
56. Watanapa P (1996). Cholangiocarcinoma in patients with opisthorchiasis. Br J Surg, 83, 1062-4.
57. Watanapa P, Watanapa W (2002). Liver fluke-associated cholangiocarcinoma. Br J Surg, 89, 962.
58. Williams KJ, Picus J, Trinkhaus K, et al (2010). Gemcitabine with carboplatin for advanced biliary tract cancers: a phase II single institution study. HPB (Oxford), 12, 418-26.
59. Wong LL, Lurie F, Takanishi DM (2007). Other primary neoplasms in patients with hepatocellular cancer: prognostic implications? Hawaii Med J, 66, 204, 206-8.
60. Yu MW, Hsu FC, Sheen IS, et al (1997). Prospective study of hepatocellular carcinoma and liver cirrhosis in asymptomatic chronic hepatitis B virus carriers. Am J Epidemiol, 145, 1039-47.